Jaruseviciene Ruta, Sirvydyte Ginte
Center of Eye Diseases, Clinic of Ear, Nose, Throat and Eye Diseases, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Vilnius, Lithuania.
BMC Ophthalmol. 2020 Sep 22;20(1):375. doi: 10.1186/s12886-020-01635-2.
Side effects of the systemic drugs used to treat eyes are not common. Triplixam is used to treat systemic hypertension and contains amlodipine, indapamide and perindopril arginine as active ingredients which might have induced the sudden myopia. The transient myopia with objective findings disappeared after the discontinuation of the drug.
A 33-year-old male presented to the emergency department with a history of blurred vision in both eyes. Development of myopia, lens thickening, choroidal effusion and retinal striae at the macula with the increase in macular thickness was observed in both eyes. These symptoms cleared completely after the drug was discontinued. Myopisation could have been caused by lens thickening and changing its refractive index as a result of allergic or idiosyncratic reaction of the ciliary body. Retinal striae may be caused by the volume effect of the choroidal effusion.
Our report describes the adverse effect of Triplixam, probably resulting from its ingredient indapamide. Although indapamide is a common drug used in the treatment of systemic hypertension, it is important for cardiologists, general practitioners and other physicians to be aware of the possible adverse effect of Triplixam.
用于治疗眼部的全身性药物的副作用并不常见。Triplixam用于治疗全身性高血压，其活性成分包括氨氯地平、吲达帕胺和培哚普利精氨酸，这些成分可能导致了突发性近视。停药后，伴有客观检查结果的短暂性近视消失。
一名33岁男性因双眼视力模糊的病史就诊于急诊科。双眼均出现近视、晶状体增厚、脉络膜积液以及黄斑区视网膜条纹，且黄斑厚度增加。停药后这些症状完全消失。近视可能是由于睫状体的过敏或特异反应导致晶状体增厚并改变其折射率所致。视网膜条纹可能是脉络膜积液的容积效应引起的。
我们的报告描述了Triplixam的不良反应，可能是由其成分吲达帕胺引起的。尽管吲达帕胺是治疗全身性高血压的常用药物，但心脏病专家、全科医生和其他医生了解Triplixam可能的不良反应很重要。
